1. Aide
    1. Espace Client
    2. Connexion
  1. Aide
    1. Espace Client
    2. Connexion
Espace Membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre



274.500 (c) CHF
valeur indicative 246.600 EUR

CH0012032048 ROG

SIX Swiss Exchange données temps différé
  • ouverture


  • clôture veille


  • + haut


  • + bas


  • volume

    1 082 868

  • valorisation

    192 854 MCHF

  • capital échangé


  • dernier échange

    26.06.19 / 17:31:19

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?



  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?



  • rendement estimé 2019


  • PER estimé 2019

    Qu'est-ce que le PER ?



  • dernier dividende


  • date dernier dividende


  • Éligibilité


  • + Alerte

  • + Portefeuille

  • + Liste

Retour au sujet ROCHE GS

ROCHE HLDG DR : Nouvelle de l'AG 4 mars dividende 4.60

04 mars 200817:16

Basel, 4 March 2008

Roche raises dividend by 35 percent
Annual General Meeting approves Annual Report and financial statements for 2007

Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 662 shareholders in attendance, representing 143,480,308, or 89.7% of a total of 160,000,000 bearer shares, approved the 2007 Annual Report and financial statements. They also authorised a 35% increase in the gross dividend to 4.60 Swiss francs per share and non-voting equity, the twenty-first dividend increase in as many years. The Annual General Meeting also voted to reduce the term of office of directors from four years to three. Bruno Gehrig, Lodewijk J.R. de Vink, Walter Frey and Andreas Oeri were re-elected to the Board of Directors for a further term of office.

In his address to shareholders, Chairman and CEO Franz B. Humer summed up the year as follows: “Roche achieved outstanding results in 2007, continuing the extremely positive development of business seen in recent years. Roche’s growth is very broadly based and will be virtually unaffected by patent expiries in the next few years. Significant challenges and opportunities lie ahead in the healthcare market, and we will be able to tackle them with confidence from a position of strength.”

Dr Humer also emphasised Roche’s pioneering role in the development of personalised healthcare solutions. The concept of personalised medicine uses the genetic differences between patients to develop treatments and tests that are tailored to the needs of specific patient populations.

As of today’s meeting Severin Schwan has succeeded Franz B. Humer as CEO of the Roche Group. In his first speech the new CEO said that “Roche’s strategy is unique and we must use it as a basis for successfully advancing the company over the next years. It is an unfortunate fact that medicines are currently not as effective as they could be in an average of around fifty percent of patients, and in certain indications the success rate is even lower. This is why Roche is systematically pursuing personalised medicine – it is an approach that is capable of increasing the safety, efficacy and cost-efficiency of treatment. And there is no company in the world in a better position to make this approach reality.”

Signaler un abus

Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

0 réponse

Retour au sujet ROCHE GS

Signaler le message


Qui a recommandé ce message ?


Mes listes

Une erreur est survenue pendant le chargement de la liste




5500.72 -0.25%
0.7915 +9.02%
1.13638 -0.06%
3.43 +0.94%
66.28 -0.12%

Les Risques en Bourse